Non Hodgkin Lymphoma

Methods of T Cell Depletion Trial (MoTD)

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Methionine PET/CT Studies In Patients With Cancer

Familial Investigations of Childhood Cancer Predisposition

Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy

A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics

Pre-malignant States to Hematologic Malignancies in Firefighters

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors

Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma

Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Improving Exercise Capacity With a Tailored Physical Activity Intervention

SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas

Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)

Impact of Respiratory Training in Lymphoma Survivors

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies